Mannitol is a commonly administered hyperosmolar agent for a variety of clinical indications. Introduced into patient care 50+ years ago, it is claimed that mannitol delivers clinical benefits by reducing elevated intracranial pressure (ICP),1–5 enhancing operative conditions for craniotomy,6 and providing renoprotection during kidney transplantation.7,8
Although considered to have a favorable safety profile, questions remain concerning mannitol’s clinical efficacy and the associated impacts on physiology and outcomes. The clinical significance of this uncertainty is increasing, as investigation into hypertonic saline as an alternative osmotherapy has recently grown.9,10 Given the presence of ambiguous research findings and the clinical complexity of patients requiring hyperosmolar therapy, physician preference has traditionally played a significant role in mannitol application.
Quality randomized controlled trials (RCTs) that specifically compare mannitol versus a control therapy are essential to determining the optimal use of mannitol. In this paper, we aim to systematically review and summarize the evidence pertinent to mannitol’s clinical efficacy, based on the RCTs conducted since mannitol’s clinical debut. We also aim to systematically review the reported complications attributed to mannitol administration. Meta-analysis is performed when feasible.
HISTORY OF MANNITOL
Weed and McKibben11 proposed the hyperosmolar theory for reducing raised ICP in 1919, based on the observation that cerebrospinal fluid pressure decreased following hypertonic saline-induced intravascular osmotic shifts in etherized cats. This discovery prompted the search for an optimal osmotherapy in neurological patients with elevated ICP. Although urea was considered early on,12 mannitol eventually emerged as the agent of choice in the early 1960s.13 Before this introduction into clinical neuroscience, mannitol was investigated as an alternative to inulin to measure glomerular filtration rate14 and as a treatment for edema secondary to nephrosis.15
In 1961, Wise and Chater13 reported that administering mannitol in canines (and a human subject with a brain tumor) lowered cerebrospinal fluid pressure. Wise and Chater16 followed this proof of concept study in rapid succession with a study of 24 human subjects and a publication in 1962 that formally introduced the potential therapeutic indications for intravenous mannitol administration.17 Also in 1962, Shenkin et al18 published a report of 34 patients supporting the use of mannitol for brain relaxation during craniotomy by determining that satisfactory operative conditions were achieved in all cases. Eventually, mannitol replaced urea as the standard of care for brain relaxation because of a more favorable profile in regards to preparation, chemical stability, and safety.19
More recently, hypertonic saline has emerged as an alternative hyperosmolar therapy.20,21 The clinical efficacy of hypertonic saline was demonstrated by Todd et al22 in 1985, with successive research suggesting that it may outperform mannitol for brain relaxation23,24 and ICP reduction.25–27 Despite accumulating research, there is no consensus concerning the optimal osmotherapeutic agent in critical care and surgery. For example, the 2017 Guidelines for the Management of Severe Traumatic Brain Injury recommended mannitol for raised ICP because of the lack of sufficient evidence supporting hypertonic saline as a replacement.28
APPLIED PHARMACOLOGY AND PHYSIOLOGY
Mannitol, which in alternate settings may be referred to as mannite or manna sugar, is a 6-carbon hexahydric alcohol with a molecular weight of 182.17 g/mol.29 A solution of 20% mannitol provides an osmolality of 1245 mOsm/kg.30 Renal excretion eliminates approximately 80% of administered mannitol, with hepatic metabolism playing a minor role.31 In humans, the distribution and elimination half-lives of mannitol are ~2 and ~71 minutes, respectively; whereas the volume of distribution and total body clearance are ~0.47 L/kg and ~7 mL/min/kg, respectively.31
Mannitol administration exerts a rapid and reliable increase in total serum osmolality. Alterations in osmotic gradients between different compartments, especially between the intracellular and extracellular space and between the intravascular and extravascular space, drive the movement of free water and provide the foundation of mannitol’s osmotherapeutic efficacy.32 The increase in serum osmolality is mitigated by the renal excretion of mannitol33 and dilution secondary to intravascular volume expansion.34 Mannitol also causes considerable diuresis, which modulates changes to serum osmolality by free water and sodium loss.35–37 Depending on the administration rate, serum osmolality normally increases until the infusion is discontinued, with a subsequent decrease driven primarily by the renal elimination of mannitol and changes in serum free water.
The effect of mannitol in neurological patients relies on the integrity of the blood brain barrier, which restricts the passage of mannitol and allows the movement of free water.32 The loss of free water in brain parenchyma (primarily from the intracellular and extravascular spaces) leads to a decrease in brain bulk that in turn leads to brain relaxation when the dura is opened and ICP reduction when the dura is closed.6
Mannitol may also affect the intravascular space of the brain. In cats, mannitol leads to cerebral vasoconstriction, which is likely a regulatory response to the decrease in blood viscosity and the consequential increase in cerebral blood flow (CBF).38 In theory, cerebral vasoconstriction may reduce cerebral blood volume, which in turn may facilitate brain shrinkage.
EVIDENCE BASED ON RANDOMIZED CONTROLLED TRIALS
Systematic Review With Meta-Analysis
In order to understand the effects of mannitol on clinically relevant outcomes, a systematic literature search of the published RCTs with meta-analysis (when feasible) was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.39 An experienced medical librarian performed a comprehensive search of multiple databases after consulting with the lead authors and performing a Medical Subject Heading (MeSH) analysis of key articles provided by the research team. In each database, we used an iterative process to translate and refine the searches. Both English and foreign language articles were eligible. The formal search strategies used relevant vocabulary terms and synonymous free text words and phrases to capture the concepts of RCT and mannitol.
The databases searched were MEDLINE (OvidSP 1946 to September Week 2 2016), MEDLINE (PubMed, for in-process and nonindexed citations), and Embase (OvidSP 1974 to 2016 September 09). All searches were run on September 9, 2016. The full strategy for OvidSP MEDLINE is detailed in the Supplemental Digital Content File 1, http://links.lww.com/JNA/A65, and additional strategies are available from the authors. Further studies were identified by examining the reference lists of all included articles and searching Google Scholar and PubMed nonsystematically.
The inclusion criteria were (1) mannitol administered intravenously as an intervention, (2) mannitol compared to a control therapy, (3) critical care or perioperative setting, (4) RCT study design, and (5) human subjects. The exclusion criteria were (1) case reports, (2) observational studies, (3) retrospective studies, (4) review articles, (5) nonhuman studies, and (6) mannitol given orally or in an irrigation solution.
The systematic literature search yielded 2413 unique articles which were independently screened by 2 investigators (W.Z. and L.L.), with the conflicts resolved by consulting the senior investigators (F.S. and L.M.). A total of 55 RCTs were identified20,30,43–95 (Supplemental Digital Content File 2, http://links.lww.com/JNA/A66). See Figure 1 for flowchart outlining the study selection process. The risk of bias for each individual study that was eligible for meta-analysis was assessed with a tool developed by the Cochrane Collaboration.40 The domains being assessed and the results of the assessment are detailed in the Supplemental Digital Content File 3, http://links.lww.com/JNA/A67.
The outcomes of interest included: (1) ICP, (2) cerebral perfusion pressure (CPP), (3) mean arterial pressure (MAP), (4) brain relaxation, (5) serum sodium, (6) intraoperative fluid intake, and (7) intraoperative urine output (Table 1). Because of the methodological heterogeneity, not every clinically relevant outcome could be meaningfully meta-analyzed. We only performed meta-analyses if outcomes were investigated by at least 3 RCTs that used the same patient population and comparable methodologies.
The meta-analysis was performed using the Review Manager (RevMan) software (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). To account for variation or heterogeneity among various studies, the DerSimonian and Laird random-effects statistical model was applied for all analyses. I2 statistic was used to measure the degree of heterogeneity across studies. When I2 was <50%, low heterogeneity was assumed, and the effect was thought to be because of chance. Conversely, when I2 >50%, high heterogeneity was thought to exist. The statistical test of heterogeneity was undertaken by the use of Cochran’s Q-test (eg, χ2 test). For measures of effect sizes, risk ratio (RR) with 95% confidence interval (CI) was calculated for dichotomous outcomes. Standardized mean difference (SMD) with 95% CI was calculated for continuous outcomes. A P-value<0.05 was considered to be statistically significant.
Traumatic Brain Injury (TBI)
TBI is associated with significant morbidity and mortality. It leads to ~235,000 hospitalizations and ~50,000 deaths per year in the United States.96 The goals of mannitol administration in patients with TBI are to decrease ICP, increase CPP, and reduce the risk of cerebral ischemia and brain herniation.97
The literature search identified 11 RCTs comparing mannitol versus a control therapy in patients with TBI (Supplemental Digital Content File 2, http://links.lww.com/JNA/A66). Meta-analysis was performed for MAP and serum sodium concentration. There was no difference in posttreatment MAP between mannitol and hypertonic saline (SMD [95% CI]=−3.3 [−7.9, 1.3] mm Hg; P=0.16) (Fig. 2A). The serum sodium concentration measured 15 to 120 minutes after administration was significantly lower for mannitol compared with hypertonic saline (SMD [95% CI]=−8.0 [−11.0, −4.9] mmol/L; P<0.00001) (Fig. 2B). Mannitol effectively decreased ICP in patients with TBI, and there was no difference in the magnitude of reduction between mannitol and the control therapy based on the reported data.30,48,49,51,52,54 We did not perform a meta-analysis of ICP because of the heterogeneity of the control therapies among these studies.
A recent meta-analysis based on 7 RCTs performed in patients with severe TBI concluded that the risk of ICP treatment failure favors hypertonic saline over mannitol (RR [95% CI]=0.39 [0.18, 0.81]; P=0.01).98 The authors were not able to directly meta-analyze changes in ICP because of the significant heterogeneity in the reporting of ICP changes from baseline.98 A different meta-analysis based on 5 RCTs, performed in patients with brain tumors, stroke, or TBI, concluded that hypertonic saline is more effective than mannitol in ICP reduction (RR [95% CI]=1.16 [1.00, 1.33]; P=0.046).99 Another meta-analysis based on 7 studies (6 RCTs and 1 retrospective study) performed in patients with TBI also concluded that hypertonic saline is more effective than mannitol in ICP reduction (SMD [95% CI]=−1.69 [−2.95, −0.44] mm Hg; P = 0.008).27 However, one meta-analysis based on 6 RCTs conducted in TBI patients failed to demonstrate the superiority of hypertonic saline over mannitol (SMD [95% CI]=1.39 [−0.74, 3.53] mm Hg; P=0.152).10
Of note, studies performed in different patient populations were included in 2 meta-analyses,27,99 whereas all previous meta-analyses were based on studies that had used different intervention protocols.10,27,98,99 Moreover, a variety of outcome measures (ie, treatment failure, relative risk, and mean difference) were used by different meta-analyses.10,27,98,99 An additional limitation was that several RCTs reported either the median (range) or the mean (SD) ICP, which could not be readily pooled together for meta-analysis. Although there exist some rules that approximate mean and SD values by certain transformations of median and range values, we opted not to do so because the reporting of different types of summary statistics implicitly suggested inherent study differences. This empirical approximation introduces another source of bias to the synthesis of heterogeneous studies. In conclusion, the predetermined methodology has a heavy influence on both the conduct and results of a meta-analysis.
All RCTs included in our meta-analysis demonstrated the efficacy of both mannitol and hypertonic saline in increasing CPP from the pretreatment level. While some studies found a larger increase in CPP after hypertonic saline than after mannitol administration,48 others failed to identify a difference between these 2 treatments.30,48,49,51 One study found that, although CPP was higher after hypertonic saline treatment, there was no statistically significant difference in mortality between mannitol and hypertonic saline treatments in patients with TBI.48 Nonetheless, a study performed in patients with TBI found that aggressive CPP management was associated with more favorable Glasgow coma scale scores and better chances of survival, even in cases of extremely high ICP.100 A review article focusing on the management of CPP in pediatric patients with head injury concluded that a higher CPP level is associated with more favorable outcomes.101 However, there were insufficient data to allow for a meta-analysis of those essential outcomes.
Mannitol increases CBF in patients with TBI,102 and this effect may be cerebral-autoregulation-functional-status dependent.103 The loss of cerebral autoregulation in patients with severe TBI renders CBF pressure-passive, and thus tight control of CPP is even more crucial for optimal brain perfusion.104 It is important to note that cerebral perfusion is determined not only by CPP and cerebrovascular resistance, a relationship defined by cerebral autoregulation,105 but also by the percentage of distribution of cardiac output (CBF is ~12% to 15% of cardiac output).106 It was also suggested by a study performed in 35 patients with severe head injuries that the decrease in blood viscosity following mannitol administration has significant impacts on CBF.107 Overall, it is likely that the impact of mannitol on CBF is primarily determined by its effects on ICP and CPP; however, changes in intravascular volume, blood viscosity, afterload, and cardiac output may also play a role.
Mannitol leads to a higher urine output than hypertonic saline in patients with TBI,49 implying that both urine output and intravascular volume need to be closely monitored following the administration of mannitol. One study demonstrated that hypertonic saline had a more beneficial effect in reducing oxidative stress than mannitol in patients with TBI 53; however, not only does this observation need to be validated by further research, the clinical significance also remains to be determined.
Critical Neurological Conditions
Several severe, nontraumatic neurological conditions are frequently associated with increased ICP. One of the therapeutic goals in these patients is to control ICP, with mild cases normally managed medically and severe cases requiring decompressive craniectomy. Mannitol has traditionally been used in these conditions as a hyperosmolar therapy.
The literature search identified 10 RCTs comparing mannitol with a control therapy in patients with ischemic stroke,20,55,61 intracranial hemorrhage,20,57–59,62 and intracranial hypertension related to other etiologies.56,60 However, because of the heterogeneous patient populations and methodologies among these studies, we were not able to meta-analyze the clinically relevant outcomes (Supplemental Digital Content File 2, http://links.lww.com/JNA/A66).
One RCT found that hypertonic saline hydroxyethyl starch was more effective in lowering ICP but less effective in increasing CPP compared with mannitol in stroke patients with intracranial hypertension.20 There were no RCTs comparing the efficacy of mannitol versus a control therapy to decrease ICP in patients with intracerebral hemorrhage. In a canine model of intracranial hemorrhage, no significant difference in ICP change was found among the therapies of 20% mannitol, 3% saline, and 23.4% saline, although it was noted that 3% saline may have a longer duration of action.108
The effects of equiosmolar doses of mannitol and hypertonic saline on CBF, measured by positron emission tomography, were compared in patients with ischemic stroke.61 Mannitol, but not hypertonic saline, seemed to be able to increase CBF in nonischemic brain tissue.61 This finding is corroborated by a nonrandomized human study which demonstrated an increase in the blood flow velocity, measured by transcranial Doppler, in the middle cerebral artery ipsilateral to intracerebral hemorrhage after mannitol administration.109
Compared with hypertonic saline, mannitol consistently decreases serum sodium concentration to a level that is deemed undesirable in neurocritical care (~128 to 129 mmol/L).56,60 However, the mannitol-related hyponatremia does not adversely affect serum osmolality. In fact, mannitol causes a slightly larger increase in serum osmolality compared with hypertonic saline (329 vs. 321 mOsm/L56 and 310 vs. 308 mOsm/L60).
We identified 4 RCTs that investigated mortality or disability associated with mannitol versus a control therapy in stroke patients. Mannitol demonstrated no superiority over control in the following metrics: (1) consciousness, motor capabilities, or sensory capabilities in patients with ischemic stroke,55 (2) Glasgow coma scale score in patients with intracranial hemorrhage,57 and (3) functional disability at 1-month and 3-month follow-up in patients with intracranial hemorrhage.58 The secondary analysis of an RCT conducted in 2839 patients with intracranial hemorrhage concluded that mannitol is a safe therapeutic option, although it might not be associated with improved 3-month mortality or disability.62 In contrast, an RCT conducted in 24 patients with intracranial hemorrhage concluded that mannitol leads to a more significant clinical improvement compared with normal saline.59 The cause of these diverse findings remains to be reconciled.
The Guidelines for the Management of Spontaneous Intracerebral Hemorrhage published in 1999 recommended 20% mannitol (0.25 to 0.5 g/kg) every 4 hours for a duration of <5 days to treat raised ICP, in patients with progressively increasing ICP values or clinical deterioration associated with mass effect.110 Although it was concluded that hypertonic saline might be more effective than mannitol in treating intracranial hypertension based on one meta-analysis,99 the updated Guidelines for the Management of Spontaneous Intracerebral Hemorrhage published in 2015 continued the previous recommendation for mannitol as an acceptable hyperosmolar therapy.111 It should be noted that the aforementioned meta-analysis was based on 5 studies performed in different patient populations (brain tumor, stroke, and TBI).99
Craniotomy procedures can be classified as elective or emergent. The primary goal of mannitol administration in elective craniotomy is to optimize operative conditions by brain relaxation.6 Brain relaxation and ICP are related but different entities. Brain relaxation refers to the relation between intracranial content and capacity with the dura opened, whereas ICP refers to the pressure generated as a result of the interaction between intracranial contents and capacity with the cranium closed.6 In contrast to elective cases, the primary goal of mannitol administration in emergent craniotomy is to facilitate ICP management (ie, avoid cerebral herniation injury), especially when the surgical indication is for decompression.
The literature search identified 19 RCTs that compared the effects of mannitol versus a control therapy in patients undergoing craniotomy (Supplemental Digital Content File 2, http://links.lww.com/JNA/A66). Meta-analysis based on 11 RCTs showed that, although mannitol could provide satisfactory brain relaxation, it was less likely than hypertonic saline to do so (RR [95% CI]=0.89 [0.81, 0.98]; P=0.02) (Fig. 3A). Meta-analysis based on 7 RCTs showed that intravenous fluid replacement was much greater in patients receiving mannitol compared with hypertonic saline (SMD [95% CI]=0.67 [0.21, 1.13] L; P=0.004) (Fig. 3B). Meta-analysis based on 8 RCTs showed that mannitol was associated with increased urine output compared with hypertonic saline (SMD [95% CI]=485 [211, 759 mL; P=0.0005) (Fig. 3C). Meta-analysis based on 6 RCTs showed that the serum sodium concentration was significantly lower after mannitol administration than after hypertonic saline administration (SMD [95% CI]=−6.2 [−9.6, −2.9] mmol/L; P=0.0002) (Fig. 3D). Finally, meta-analysis based on 7 RCTs showed that MAP was significantly higher 30 minutes after mannitol administration than after hypertonic saline administration (SMD [95% CI]=3 [0.08, 6] mm Hg; P=0.04) (Fig. 3E).
Our conclusion that hypertonic saline achieves better brain relaxation versus mannitol for elective craniotomy is supported by 3 different meta-analyses, which include a 2014 study based on 6 RCTs,112 a 2015 study based on 7 RCTs,113 and a 2017 study based on 9 RCTs.24 Although satisfactory brain relaxation is desirable during craniotomy to minimize retraction injury and/or herniation through the skull defect, only a few studies examined the relation between brain relaxation and clinical outcomes. Several studies showed that, although hypertonic saline was associated with better brain relaxation compared with mannitol, there was no difference in length of ICU or overall hospital stay between these treatments.66,74 A recent study performed in patients undergoing elective craniotomy demonstrated that higher doses of mannitol provided better brain relaxation but were also associated with more adverse effects, defined as hyponatremia with Na+ between 125 and 130 mmol/L and hyperkalemia with K+>5.0 mmol/L.114 The authors suggested that the use of 1.0 g/kg mannitol balanced the benefits associated with satisfactory brain relaxation against the risks of undesired side effects.114 The overall evidence suggests that, when poor brain relaxation per se is of primary concern, hypertonic saline is a better therapeutic option than mannitol, and when the dose of mannitol has to be escalated for better brain relaxation, the profile of blood electrolytes needs to be closely watched.
The small but statistically significant difference in MAP between mannitol and hypertonic saline treatments may not be clinically significant. In theory, cerebral autoregulation is better preserved during elective craniotomy than TBI; therefore, CPP fluctuations can be better tolerated during elective craniotomy as long as the CPP is within the autoregulatory range. Moreover, ICP becomes zero during craniotomy with the dura opened, which is different from TBI where the ICP can be dangerously high because of the closed cranium. These facts explain why a small change in MAP is less concerning during elective craniotomy than when treating TBI.
Mannitol has significant but short-lived (~15 to 25 mins) impacts on global hemodynamics during elective craniotomy. On the basis of the transesophageal echocardiography measurements, a single bolus dose of 20% mannitol (1.0 gm/kg) leads to significant increases in left ventricle preload and cardiac output and a significant decrease in afterload without concomitant changes in blood pressure and heart rate.115 This finding is corroborated by a separate study that demonstrated significant mannitol-related increases in stroke volume and cardiac output measured by thoracic bioimpedance plethysmography.116 Both studies were performed in patients undergoing elective craniotomy. The clinical significance of these hemodynamic changes remains to be elucidated.
The literature search yielded 14 RCTs comparing mannitol with a control therapy in nonneurological patients (Supplemental Digital Content File 2, http://links.lww.com/JNA/A66). Meta-analysis could not be performed because of the heterogeneity of patient populations, intervention protocols, and outcome measurements among these studies.
Historically, mannitol was used across a wide spectrum of clinical settings including: (1) renoprotection,81,83,84,86,87 (2) treatment of oliguria or anuria,80 (3) prevention of transurethral prostatectomy syndrome,82 (4) enhancement of recovery after coronary artery bypass grafting,90 (5) alleviation of the immunosuppression induced by cardiopulmonary bypass,91 (6) attenuation of postreperfusion syndrome in liver transplantation,95 and (7) optimization of the operative conditions during the repair of orbital blowout fractures.92 On the basis of the RCTs that we collected, modern indications for mannitol, aside from the clinical neuroscience, are primarily related to mannitol’s renal effects.
Mannitol administration in renal transplant has long been used to improve outcomes in kidney allograft recipients.7,117 The beneficial effects may be associated with the expansion of intravascular volume, diminished renal tubular obstruction, enhanced intrarenal vasodilatory prostaglandin and atrial natriuretic peptide release, and oxygen free-radical scavenger properties.7,117–119 However, direct RCT evidence examining the effect of mannitol administration on clinical outcomes after kidney transplantation is lacking.
SIDE EFFECTS OF MANNITOL
To understand the side effects associated with mannitol administration, we performed a systematic literature search for reported complications attributed to mannitol. Again, a professional librarian searched the same electronic bibliographic databases from inception of the databases until September 12, 2016. The full strategy for OvidSP MEDLINE search is detailed in the Supplemental Digital Content File 4, http://links.lww.com/JNA/A68, and additional strategies are available from the authors. The inclusion criteria were (1) mannitol administered, (2) complications or adverse events occurred and attributed to mannitol, and (3) human subjects.
A total of 65 reports of mannitol-related complications were identified (Supplemental Digital Content File 5, http://links.lww.com/JNA/A69).120–184 Hyponatremia and hyperkalemia were the most commonly reported electrolyte abnormalities. Abnormal electrocardiograms and cardiac arrest associated with hyperkalemia were also reported. Pulmonary edema was the most common pulmonary complication reported, which seemed to be associated with large dose mannitol administration in most cases (eg, 3250 mL of 20% mannitol given to a 7-year-old girl for cerebral edema treatment).134 Most mishaps were renal complications, with most cases diagnosed as acute renal failure. The clinical signs included oliguria, anuria, elevated creatinine, elevated blood urea nitrogen, decreased serum sodium concentration, increased serum potassium concentration, and/or increased serum glucose level. Cerebral complications included intracranial rebleeding, hematoma, brain expansion, and leakage into peritumor edematous areas causing rebound ICP increases. Cardiac complications included cardiac arrest, chest pain, pulmonary embolism, and bundle branch block. The reported gastrointestinal complications were all colonic explosions and associated with large doses of mannitol given orally. Other complications included hypertension, hypotension, and compartment syndrome likely related to mannitol subcutaneous infiltration.
Hypertonic hyponatremia is a well-documented electrolyte abnormality.185–188 The presence of effective solute other than sodium, such as mannitol, in the plasma causes an osmotic shift of water from the intracellular to extracellular space and from the extravascular to intravascular space. The expansion of the proportion of water in the plasma leads to a dilutional decrease in serum sodium concentration.185,187,188 The increased sodium loss from urine following mannitol-induced diuresis fuels the development of hyponatremia.36,37 The etiology of mannitol-induced hyperkalemia is likely multifactorial, with possible explanations including (1) expansion acidosis because of the dilution of the extracellular bicarbonate with a bicarbonate-poor fluid from the intracellular space, (2) solvent drag, which refers to the movement of potassium along with the water out of intracellular space, and (3) hemolysis secondary to red cell crenation; however, this speculation regarding hemolysis is contradictory to some experimental data and clinical experience.189–191
It is important to note that the doses of mannitol administered in many cases were very large, sometimes 10 times larger than what are currently used in clinical practice. Thus, it is possible that the reported complications were dose-related. Indeed, most literature indicates that mannitol is safe as long as the dose is within the recommended range.114 Most patients with reported complications recovered, although a few died; usually because of the progression of the primary disease. The available evidence should be interpreted with caution because it is based on case reports. Therefore, a cause-effect relationship typically cannot be determined.
Since being introduced into clinical neuroscience 50+ years ago, mannitol has remained a prominent osmotherapeutic agent. Despite such a long tenure, our understanding of its effects on essential clinical outcomes is still a work in progress. Although >50 RCTs comparing mannitol with a control therapy have been published, meaningful meta-analyses are restrained by the heterogeneity of clinical settings, intervention protocols, and outcome measures. Most evidence centers on mannitol’s physiological effects in neurological patients. The efficacy of mannitol in decreasing ICP and rendering brain relaxation in neurological patients is supported by our meta-analyses. Although potential side effects should not be overlooked, mannitol has a generally favorable safety profile when the recommended doses are used. A shift towards conducting RCTs that focus on long-term outcomes is a priority.
1. Lin SY, Tang SC, Tsai LK, et al. Incidence and risk factors for acute kidney injury following mannitol
infusion in patients with acute stroke: a retrospective cohort study. Medicine (Baltimore). 2015;94:e2032.
2. Kim MY, Park JH, Kang NR, et al. Increased risk of acute kidney injury associated with higher infusion rate of mannitol
in patients with intracranial hemorrhage. J Neurosurg. 2014;120:1340–1348.
3. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma. 2007;24(suppl 1):S14–S20.
4. Quentin C, Charbonneau S, Moumdjian R, et al. A comparison of two doses of mannitol
on brain relaxation during supratentorial brain tumor craniotomy: a randomized trial. Anesth Analg. 2013;116:862–868.
5. Bereczki D, Fekete I, Prado GF, et al. Mannitol
for acute stroke. Cochrane Database Syst Rev. 2007;3:CD001153.
6. Li J, Gelb AW, Flexman AM, et al. Definition, evaluation, and management of brain relaxation during craniotomy. Br J Anaesth. 2016;116:759–769.
7. van Valenberg PL, Hoitsma AJ, Tiggeler RG, et al. Mannitol
as an indispensable constituent of an intraoperative hydration protocol for the prevention of acute renal failure after renal cadaveric transplantation. Transplantation. 1987;44:784–788.
8. Weimar W, Geerlings W, Bijnen AB, et al. A controlled study on the effect of mannitol
on immediate renal function after cadaver donor kidney transplantation. Transplantation. 1983;35:99–101.
9. Boone MD, Oren-Grinberg A, Robinson TM, et al. Mannitol
or hypertonic saline in the setting of traumatic brain injury: What have we learned? Surg Neurol Int. 2015;6:177.
10. Rickard AC, Smith JE, Newell P, et al. Salt or sugar for your injured brain? A meta-analysis
of randomised controlled trials of mannitol
versus hypertonic sodium solutions to manage raised intracranial pressure in traumatic brain injury. Emerg Med J. 2014;31:679–683.
11. Weed LH, McKibben PS. Pressure changes in cerebrospinal fluid following injections of solutions of various concentrations. Am J Physiol. 1919;48:512–530.
12. Smythe L, Smythe G, Settlage P. The effect of intravenous urea on cerebrospinal fluid pressure in monkeys. J Neuropathol Exp Neurol. 1950;9:438–442.
13. Wise BL, Chater N. Effect of mannitol
on cerebrospinal fluid pressure. The actions of hypertonic mannitol
solutions and of urea compared. Arch Neurol. 1961;4:200–202.
14. Smith WW, Finkelstein N, Smith HW. Renal excretion of hexitols (sorbitol, mannitol
, and dulcitol) and their derivatives (sorbitan, isomannide, and sorbide) and of endogenous creatinine-like chromogen in dog and man. J Biol Chem. 1940;135:231–250.
15. Bernstein LM, Blumberg B, Arkin MC. Osmotic diuretic treatment of refractory edema. Circulation. 1958;17:1013–1020.
16. Wise BL, Chater N. Use of hypertonic mannitol
solutions to lower cerebrospinal fluid pressure and decrease brain bulk in man. Surg Forum. 1961;12:398–399.
17. Wise BL, Chater N. The value of hypertonic mannitol
solution in decreasing brain mass and lowering cerebro-spinal-fluid pressure. J Neurosurg. 1962;19:1038–1043.
18. Shenkin HA, Goluboff B, Haft H. The use of mannitol
for the reduction of intracranial pressure in intracranial surgery. J Neurosurg. 1962;19:897–901.
19. Otvos B, Kshettry VR, Benzel EC. The history of urea as a hyperosmolar agent to decrease brain swelling. Neurosurg Focus. 2014;36:E3.
20. Schwarz S, Schwab S, Bertram M, et al. Effects of hypertonic saline hydroxyethyl starch solution and mannitol
in patients with increased intracranial pressure after stroke. Stroke. 1998;29:1550–1555.
21. Pasarikovski CR, Alotaibi NM, Al-Mufti F, et al. Hypertonic saline for increased intracranial pressure after aneurysmal subarachnoid hemorrhage: a systematic review
. World Neurosurg. 2017;105:1–6.
22. Todd MM, Tommasino C, Moore S. Cerebral effects of isovolemic hemodilution with a hypertonic saline solution. J Neurosurg. 1985;63:944–948.
23. Prabhakar H, Singh GP, Anand V, et al. Mannitol
versus hypertonic saline for brain relaxation in patients undergoing craniotomy. Cochrane Database Syst Rev. 2014;7:CD010026.
24. Fang J, Yang Y, Wang W, et al. Comparison of equiosmolar hypertonic saline and mannitol
for brain relaxation during craniotomies: a meta-analysis
of randomized controlled trials
. Neurosurg Rev. 2018;41:945–956.
25. Zornow MH. Hypertonic saline as a safe and efficacious treatment of intracranial hypertension. J Neurosurg Anesthesiol. 1996;8:175–177.
26. Ziai WC, Toung TJ, Bhardwaj A. Hypertonic saline: first-line therapy for cerebral edema? J Neurol Sci. 2007;261:157–166.
27. Li M, Chen T, Chen SD, et al. Comparison of equimolar doses of mannitol
and hypertonic saline for the treatment of elevated intracranial pressure after traumatic brain injury: a systematic review
. Medicine (Baltimore). 2015;94:e736.
28. Carney N, Totten AM, O’Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80:6–15.
29. Nissenson AR, Weston RE, Kleeman CR. Mannitol
. West J Med. 1979;131:277–284.
30. Battison C, Andrews PJ, Graham C, et al. Randomized, controlled trial on the effect of a 20% mannitol
solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med. 2005;33:196–202; discussion 257-8.
31. Cloyd JC, Snyder BD, Cleeremans B, et al. Mannitol
pharmacokinetics and serum osmolality in dogs and humans. J Pharmacol Exp Ther. 1986;236:301–306.
32. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS. 2014;11:26.
33. Dominguez R, Corcoran AC, Page IH. Mannitol
: kinetics of distribution, excretion, and utilization in human beings. J Lab Clin Med. 1947;32:1192–1202.
34. Rudehill A, Lagerkranser M, Lindquist C, et al. Effects of mannitol
on blood volume and central hemodynamics in patients undergoing cerebral aneurysm surgery. Anesth Analg. 1983;62:875–880.
35. Ambuhl PM, Ballmer PE, Krahenbuhl S, et al. Quantification and predictors of plasma volume expansion from mannitol
treatment. Intensive Care Med. 1997;23:1159–1164.
36. Cheney FW Jr, Rand PW, Lincoln JR. Mannitol
-induced diuresis. Its effect on serum and urine sodium concentration. Arch Surg. 1964;88:197–205.
37. Jagannatha AT, Kamath S, Devi I, et al. 376 The salt versus sugar debate: urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol
in severe traumatic brain injury. Neurosurgery. 2016;63(suppl 1):212.
38. Muizelaar JP, Wei EP, Kontos HA, et al. Mannitol
causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes. J Neurosurg. 1983;59:822–828.
39. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
40. Jorgensen L, Paludan-Muller AS, Laursen DR, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Syst Rev. 2016;5:80.
41. Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. J Neurol Neurosurg Psychiatry. 2004;75:813–821.
42. Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: management protocol and clinical results. J Neurosurg. 1995;83:949–962.
43. Gemma M, Cozzi S, Tommasino C, et al. 7.5% hypertonic saline versus 20% mannitol
during elective neurosurgical supratentorial procedures. J Neurosurg Anesthesiol. 1997;9:329–334.
44. Rozet I, Tontisirin N, Muangman S, et al. Effect of equiosmolar solutions of mannitol
versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology. 2007;107:697–704.
45. Schwartz ML, Tator CH, Rowed DW, et al. The University of Toronto head injury treatment study: a prospective, randomized comparison of pentobarbital and mannitol
. Can J Neurol Sci. 1984;11:434–440.
46. Biestro A, Alberti R, Galli R, et al. Osmotherapy for increased intracranial pressure: comparison between mannitol
and glycerol. Acta Neurochir (Wien). 1997;139:725–732; discussion 732-3.
47. Vialet R, Albanese J, Thomachot L, et al. Isovolume hypertonic solutes (sodium chloride or mannitol
) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol
. Crit Care Med. 2003;31:1683–1687.
48. Harutjunyan L, Holz C, Rieger A, et al. Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol
15% in the treatment of increased intracranial pressure in neurosurgical patients - a randomized clinical trial [ISRCTN62699180]. Crit Care. 2005;9:R530–R540.
49. Francony G, Fauvage B, Falcon D, et al. Equimolar doses of mannitol
and hypertonic saline in the treatment of increased intracranial pressure. Crit Care Med. 2008;36:795–800.
50. Ichai C, Armando G, Orban JC, et al. Sodium lactate versus mannitol
in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med. 2009;35:471–479.
51. Cottenceau V, Masson F, Mahamid E, et al. Comparison of effects of equiosmolar doses of mannitol
and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. J Neurotrauma. 2011;28:2003–2012.
52. Sakellaridis N, Pavlou E, Karatzas S, et al. Comparison of mannitol
and hypertonic saline in the treatment of severe brain injuries. J Neurosurg. 2011;114:545–548.
53. Mojtahedzadeh M, Ahmadi A, Mahmoodpoor A, et al. Hypertonic saline solution reduces the oxidative stress responses in traumatic brain injury patients. J Res Med Sci. 2014;19:867–874.
54. Jagannatha AT, Sriganesh K, Devi BI, et al. An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol
and hypertonic saline. J Clin Neurosci. 2016;27:68–73.
55. Santambrogio S, Martinotti R, Sardella F, et al. Is there a real treatment for stroke? Clinical and statistical comparison of different treatments in 300 patients. Stroke. 1978;9:130–132.
56. Erard AC, Walder B, Ravussin P. Effects of equiosmolar load of 20% mannitol
, 7.5% saline and 0.9% saline on plasma osmolarity, haemodynamics and plasma concentrations of electrolytes. Ann Fr Anesth Reanim. 2003;22:18–24.
57. Kalita J, Misra UK, Ranjan P, et al. Effect of mannitol
on regional cerebral blood flow in patients with intracerebral hemorrhage. J Neurol Sci. 2004;224:19–22.
58. Misra UK, Kalita J, Ranjan P, et al. Mannitol
in intracerebral hemorrhage: a randomized controlled study. J Neurol Sci. 2005;234:41–45.
59. Misra UK, Kalita J, Vajpayee A, et al. Effect of single mannitol
bolus in intracerebral hemorrhage. Eur J Neurol. 2007;14:1118–1123.
60. Upadhyay P, Tripathi VN, Singh RP, et al. Role of hypertonic saline and mannitol
in the management of raised intracranial pressure in children: a randomized comparative study. J Pediatr Neurosci. 2010;5:18–21.
61. Diringer MN, Scalfani MT, Zazulia AR, et al. Cerebral hemodynamic and metabolic effects of equi-osmolar doses mannitol
and 23.4% saline in patients with edema following large ischemic stroke. Neurocrit Care. 2011;14:11–17.
62. Wang X, Arima H, Yang J, et al. Mannitol
and outcome in intracerebral hemorrhage: propensity score and multivariable intensive blood pressure reduction in acute cerebral hemorrhage trial 2 results. Stroke. 2015;46:2762–2767.
63. De Vivo P, Del Gaudio A, Ciritella P, et al. Hypertonic saline solution: a safe alternative to mannitol
18% in neurosurgery. Minerva Anestesiol. 2001;67:603–611.
64. Afifi W, Abdallah I, Yosry M. The effect of a single dose of 3% hypertonic saline versus mannitol
20% for treatment of brain oedema and intracranial hypertension in postoperative patients with supratentorial gliomata. Egyptian J Anaesthesia. 2003;19:371–379.
65. Chen J-y, Zhou S-j, Tang H-y, et al. Feasibility of reducing intracranlal pressure with 3% hypertonic saline in patients with brain tumor. Chin J Anesthesiol. 2005;25:485–489.
66. Wu CT, Chen LC, Kuo CP, et al. A comparison of 3% hypertonic saline and mannitol
for brain relaxation during elective supratentorial brain tumor surgery. Anesth Analg. 2010;110:903–907.
67. Aboeldahab H, Hegazy A, Salah A, et al. Is the usage of mannitol
mandatory in awake craniotomy? A comparative study. Egyptian J Anaesth. 2011;27:39–44.
68. Demneri M, Hoxha A, Pilika K, et al. Comparison of 20% mannitol
and 7.5% hypertonic saline for supratentorial craniotomy: 7AP5-5. Eur J Anaesthesiol (EJA). 2011;28:106–107.
69. Vilas Boas WW, Marques MB, Alves A. Hydroelectrolytic balance and cerebral relaxation with hypertonic isoncotic saline versus mannitol
(20%) during elective neuroanesthesia. Rev Bras Anestesiol. 2011;61:456–468.
70. Attari MA, Kazemian Abyaneh HR. Comparison of the effects of hypertonic saline 3.2% and mannitol
20% on brain relaxation during brain tumor surgery. J Isfahan Med Sch. 2012;30:1386–1392.
71. Mousa SA, Ramadan TH, Kassem M. Brain relaxation and electrolyte balance during resection of posterior fossa tumors under sitting position: mannitol
versus placebo. Egyptian J Anaesth. 2013;29:255–265.
72. Gayatri P, Misra S, Menon G, et al. Transesophageal echocardiographic evaluation of left ventricular systolic and diastolic function in response to 20% mannitol
and 3% hypertonic saline infusion in neurosurgical patients undergoing craniotomy. J Neurosurg Anesthesiol. 2014;26:187–191.
73. Li Q, Xu M, Zhou JX. Correlation of measured and calculated serum osmolality during mannitol
or hypertonic saline infusion in patients after craniotomy: a study protocol and statistical analysis plan for a randomised controlled trial. BMJ Open. 2014;4:e004921.
74. Malik ZA, Mir SA, Naqash IA, et al. A prospective, randomized, double blind study to compare the effects of equiosmolar solutions of 3% hypertonic saline and 20% mannitol
on reduction of brain-bulk during elective craniotomy for supratentorial brain tumor resection. Anesth Essays Res. 2014;8:388–392.
75. Dostal P, Schreiberova J, Dostalova V, et al. Effects of hypertonic saline and mannitol
on cortical cerebral microcirculation in a rabbit craniotomy model. BMC Anesthesiol. 2015;15:88.
76. Hernández-Palazón J, Fuentes-García D, Doménech-Asensi P, et al. Equiosmolar solutions of hypertonic saline and mannitol
do not impair blood coagulation during elective intracranial surgery. J Neurosurg Anesthesiol. 2017;29:8–13.
77. Li Q, Chen H, Hao JJ, et al. Agreement of measured and calculated serum osmolality during the infusion of mannitol
or hypertonic saline in patients after craniotomy: a prospective, double-blinded, randomised controlled trial. BMC Anesthesiol. 2015;15:138.
78. Raghava A, Bidkar PU, Prakash MV, et al. Comparison of equiosmolar concentrations of hypertonic saline and mannitol
for intraoperative lax brain in patients undergoing craniotomy. Surg Neurol Int. 2015;6:73.
79. Hernandez-Palazon J, Fuentes-Garcia D, Domenech-Asensi P, et al. A comparison of equivolume, equiosmolar solutions of hypertonic saline and mannitol
for brain relaxation during elective supratentorial craniotomy. Br J Neurosurg. 2016;30:70–75.
80. Jarnberg PO, Eklund J, Granberg PO. Acute effects on furosemide and mannitol
on renal function in the early postoperative period. Acta Anaesthesiol Scand. 1978;22:173–183.
81. Gubern JM, Sancho JJ, Simo J, et al. A randomized trial on the effect of mannitol
on postoperative renal function in patients with obstructive jaundice. Surgery. 1988;103:39–44.
82. Crowley K, Clarkson K, Hannon V, et al. Diuretics after transurethral prostatectomy: a double-blind controlled trial comparing frusemide and mannitol
. Br J Anaesth. 1990;65:337–341.
83. Plusa SM, Clark NW. Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a comparison of mannitol
-induced diuresis and oral sodium taurocholate. J R Coll Surg Edinb. 1991;36:303–305.
84. Nicholson ML, Baker DM, Hopkinson BR, et al. Randomized controlled trial of the effect of mannitol
on renal reperfusion injury during aortic aneurysm surgery. Br J Surg. 1996;83:1230–1233.
85. Pakulski C, Sagan L, Bohatyrewicz R. Influence of 20% mannitol
on the serum potassium level in humans, during general anesthesia. Med Sci Monit. 1998;4:CR656–CR660.
86. Dural O, Ozkara A, Celebioglu B. Comparative study of dopamine and mannitol
effects on renal function during cardiopulmonary bypass by using N-acetyl-β-D-glucosaminidase assay. Turk J Med Sci. 2000;30:453–457.
87. Whitta RK, Marshall C, Bates S, et al. Intraoperative mannitol
does not prevent renal failure in orthotopic liver transplantation. Crit Care Resusc. 2001;3:75–80.
88. Ogiste JS, Nejat RJ, Rashid HH, et al. The role of mannitol
in alleviating renal injury during extracorporeal shock wave lithotripsy. J Urol. 2003;169:875–877.
89. Kostopanagiotou G, Pandazi AK, Andreadou I, et al. Effects of mannitol
in the prevention of lipid peroxidation during liver resection with hepatic vascular exclusion. J Clin Anesth. 2006;18:570–574.
90. Shim JK, Choi SH, Oh YJ, et al. The effect of mannitol
on oxygenation and creatine kinase MB release in patients undergoing multivessel off-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2007;133:704–709.
91. Ziegeler S, Raddatz A, Schneider SO, et al. Effects of haemofiltration and mannitol
treatment on cardiopulmonary-bypass induced immunosuppression. Scand J Immunol. 2009;69:234–241.
92. Shin KJ, Lee DG, Park HM, et al. The merits of mannitol
in the repair of orbital blowout fracture. Arch Plast Surg. 2013;40:721–727.
93. Zhou X, Wu MC, Wang YL, et al. Mannitol
improves cerebral oxygen content and postoperative recovery after prolonged retroperitoneal laparoscopy. Surg Endosc. 2013;27:1166–1171.
94. Kalimeris K, Nikolakopoulos N, Riga M, et al. Mannitol
and renal dysfunction after endovascular aortic aneurysm repair procedures: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28:954–959.
95. Sahmeddini MA, Zahiri S, Khosravi MB, et al. Effect of mannitol
on postreperfusion cardiac output and central venous oxygen saturation during orthotopic liver transplant: a double-blind randomized clinical trial. Prog Transplant. 2014;24:121–125.
96. Centers for Disease C, Prevention. Rates of hospitalization related to traumatic brain injury—nine states, 2003. MMWR Morb Mortal Wkly Rep. 2007;56:167–170.
97. Wakai A, McCabe A, Roberts I, et al. Mannitol
for acute traumatic brain injury. Cochrane Database Syst Rev. 2013;8:CD001049.
98. Burgess S, Abu-Laban RB, Slavik RS, et al. A systematic review
of randomized controlled trials
comparing hypertonic sodium solutions and mannitol
for traumatic brain injury: implications for emergency department management. Ann Pharmacother. 2016;50:291–300.
99. Kamel H, Navi BB, Nakagawa K, et al. Hypertonic saline versus mannitol
for the treatment of elevated intracranial pressure: a meta-analysis
of randomized clinical trials. Crit Care Med. 2011;39:554–559.
100. Young JS, Blow O, Turrentine F, et al. Is there an upper limit of intracranial pressure in patients with severe head injury if cerebral perfusion pressure is maintained? Neurosurg Focus. 2003;15:E2.
101. Chambers IR, Kirkham FJ. What is the optimal cerebral perfusion pressure in children suffering from traumatic coma? Neurosurg Focus. 2003;15:E3.
102. Mendelow AD, Teasdale GM, Russell T, et al. Effect of mannitol
on cerebral blood flow and cerebral perfusion pressure in human head injury. J Neurosurg. 1985;63:43–48.
103. Muizelaar JP, Lutz HA III, Becker DP. Effect of mannitol
on ICP and CBF and correlation with pressure autoregulation in severely head-injured patients. J Neurosurg. 1984;61:700–706.
104. Rangel-Castilla L, Gasco J, Nauta HJ, et al. Cerebral pressure autoregulation in traumatic brain injury. Neurosurg Focus. 2008;25:E7.
105. Meng L, Gelb AW. Regulation of cerebral autoregulation by carbon dioxide. Anesthesiology. 2015;122:196–205.
106. Meng L, Hou W, Chui J, et al. Cardiac output and cerebral blood flow: the integrated regulation of brain perfusion in adult humans. Anesthesiology. 2015;123:1198–1208.
107. Bouma GJ, Muizelaar JP. Relationship between cardiac output and cerebral blood flow in patients with intact and with impaired autoregulation. J Neurosurg. 1990;73:368–374.
108. Qureshi AI, Wilson DA, Traystman RJ. Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol
and hypertonic saline. Neurosurgery. 1999;44:1055–1063; discussion 1063-4.
109. Vicenzini E, Ricciardi MC, Zuco C, et al. Effects of a single mannitol
bolus on cerebral hemodynamics in intracerebral hemorrhage: a transcranial Doppler study. Cerebrovasc Dis. 2011;32:447–453.
110. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30:905–915.
111. Hemphill JC III, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2015;46:2032–2060.
112. Prabhakar H, Singh GP, Anand V, et al. Mannitol
versus hypertonic saline for brain relaxation in patients undergoing craniotomy. Sao Paulo Med J. 2015;133:166–167.
113. Shao L, Hong F, Zou Y, et al. Hypertonic saline for brain relaxation and intracranial pressure in patients undergoing neurosurgical procedures: a meta-analysis
of randomized controlled trials
. PLoS One. 2015;10:e0117314.
114. Seo H, Kim E, Jung H, et al. A prospective randomized trial of the optimal dose of mannitol
for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection. J Neurosurg. 2017;126:1839–1846.
115. Chatterjee N, Koshy T, Misra S, et al. Changes in left ventricular preload, afterload, and cardiac output in response to a single dose of mannitol
in neurosurgical patients undergoing craniotomy: a transesophageal echocardiographic study. J Neurosurg Anesthesiol. 2012;24:25–29.
116. Sabharwal N, Rao GS, Ali Z, et al. Hemodynamic changes after administration of mannitol
measured by a noninvasive cardiac output monitor. J Neurosurg Anesthesiol. 2009;21:248–252.
117. Tiggeler RG, Berden JH, Hoitsma AJ, et al. Prevention of acute tubular necrosis in cadaveric kidney transplantation by the combined use of mannitol
and moderate hydration. Ann Surg. 1985;201:246–251.
118. Johnston PA, Bernard DB, Perrin NS, et al. Prostaglandins mediate the vasodilatory effect of mannitol
in the hypoperfused rat kidney. J Clin Invest. 1981;68:127–133.
119. Bratell S, Folmerz P, Hansson R, et al. Effects of oxygen free radical scavengers, xanthine oxidase inhibition and calcium entry-blockers on leakage of albumin after ischaemia. An experimental study in rabbit kidneys. Acta Physiol Scand. 1988;134:35–41.
120. Kirschenbaum MA. Severe mannitol
-induced hyponatremia complicating transurethral prostatic resection. J Urol. 1979;121:687–688.
121. Berry AJ, Peterson ML. Hyponatremia after mannitol
administration in the presence of renal failure. Anesth Analg. 1981;60:165–167.
122. Fournier JP, Bernardin G, Ferrari E, et al. Threatening hyperkalemia caused by mannitol
. A little-known side effect. Presse Med. 1988;17:824.
123. Robblee JA, Crosby E, Keon WJ. Hypoxemia after intraluminal oxygen line obstruction during cardiopulmonary bypass. Ann Thorac Surg. 1989;48:575–576.
124. Kitoh T, Nagasawa M, Ichinose A, et al. Severe hyponatremia induced with mannitol
in a patient with Bartter’s syndrome. J Anesth. 1994;8:236–238.
125. Soroker D, Ezri T, Szmuk P, et al. Perioperative torsade de pointes ventricular tachycardia induced by hypocalcemia and hypokalemia. Anesth Analg. 1995;80:630–633.
126. Seto A, Murakami M, Fukuyama H, et al. Ventricular tachycardia caused by hyperkalemia after administration of hypertonic mannitol
. Anesthesiology. 2000;93:1359–1361.
127. Hirota K, Hara T, Hosoi S, et al. Two cases of hyperkalemia after administration of hypertonic mannitol
during craniotomy. J Anesth. 2005;19:75–77.
128. Kimura S, Ogawa H, Katayama Y. Hyperkalemia caused by intravenous administration of mannitol
in a patient with arteriovenous malformation: case report. No Shinkei Geka. 2006;34:51–56.
129. Hassan ZU, Kruer JJ, Fuhrman TM. Electrolyte changes during craniotomy caused by administration of hypertonic mannitol
. J Clin Anesth. 2007;19:307–309.
130. Flynn BC. Hyperkalemic cardiac arrest with hypertonic mannitol
infusion: the strong ion difference revisited. Anesth Analg. 2007;104:225–226.
131. Lee GY, Han JI, Heo HJ. Severe hypocalcemia caused by absorption of sorbitol-mannitol
solution during hysteroscopy. J Korean Med Sci. 2009;24:532–534.
132. Tobita K, Kohno T. Case of hyperkalemia after the administration of hypertonic mannitol
during craniotomy. Masui. 2010;59:641–644.
133. Fanous AA, Tick RC, Gu EY, et al. Life-threatening mannitol
-induced hyperkalemia in neurosurgical patients. World Neurosurg. 2016;91:672.e5–672.e9.
134. Hartemann E, Gueho A, Rigal D, et al. Acute pulmonary oedema related to the administration of mannitol
. Two cases (author’s transl). Ann Pediatr (Paris). 1981;28:209–213.
135. Grabie MT, Gipstein RM, Adams DA, et al. Contraindications for mannitol
in aphakic glaucoma. Am J Ophthalmol. 1981;91:265–267.
136. Yun JJ, Cheong I. Mannitol
-induced hyperosmolal hyponatraemia. Intern Med J. 2008;38:73.
137. Wang JH, He Q, Liu YL, et al. Pulmonary edema in the transurethral resection syndrome induced with mannitol
5%. Acta Anaesthesiol Scand. 2009;53:1094–1096.
138. Tiller DJ, Field M, Horvath JS. Use of mannitol
in renal failure. Med J Aust. 1981;2:151.
139. Whelan TV, Bacon ME, Madden M, et al. Acute renal failure associated with mannitol
intoxication. Report of a case. Arch Intern Med. 1984;144:2053–2055.
140. Goldwasser P, Fotino S. Acute renal failure following massive mannitol
infusion. Appropriate response of tubuloglomerular feedback? Arch Intern Med. 1984;144:2214–2216.
141. Gutschenritter PW, Newcomer KL, Dahlberg PJ. Mannitol
-induced renal insufficiency. Wis Med J. 1985;84:16–17.
142. Weaver A, Sica DA. Mannitol
-induced acute renal failure. Nephron. 1987;45:233–235.
143. Rello J, Triginer C, Sanchez JM, et al. Acute renal failure following massive mannitol
infusion. Nephron. 1989;53:377–378.
144. Horgan KJ, Ottaviano YL, Watson AJ. Acute renal failure due to mannitol
intoxication. Am J Nephrol. 1989;9:106–109.
145. Huff JS. Acute mannitol
intoxication in a patient with normal renal function. Am J Emerg Med. 1990;8:338–339.
146. Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol
-induced acute renal failure. Medicine (Baltimore). 1990;69:153–159.
147. Biesenbach G, Zazgornik J, Kaiser W, et al. Severe tubulopathy and kidney graft rupture after coadministration of mannitol
and ciclosporin. Nephron. 1992;62:93–96.
148. Suzuki K, Miki M, Ono Y, et al. Acute renal failure following mannitol
infusion. Hinyokika Kiyo. 1993;39:721–724.
149. Rabetoy GM, Fredericks MR, Hostettler CF. Where the kidney is concerned, how much mannitol
is too much? Ann Pharmacother. 1993;27:25–28.
150. Docci D, Berardi E, Baldrati L. Mannitol
-induced acute renal failure. Nephron. 1994;68:141.
151. Hung KY, Tsai TJ, Hsieh BS. Mannitol
-induced acute renal failure successfully treated with peritoneal dialysis. Perit Dial Int. 1995;15:85–87.
152. Lin SL, Hung KY, Wu FL, et al. Mannitol
-induced acute renal failure. Nephrol Dial Transplant. 1995;10:120–122.
153. Nakhoul F, Better OS. Acute renal failure following massive mannitol
infusion and enalapril treatment. Clin Nephrol. 1995;44:118–120.
154. Gadallah MF, Lynn M, Work J. Case report: mannitol
nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms. Am J Med Sci. 1995;309:219–222.
155. Halma C. Mannitol
poisoning: anuria caused by a diuretic. Ned Tijdschr Geneeskd. 1996;140:1822–1824.
156. Sakemi T, Ikeda Y, Ohtsuka N, et al. Acute renal failure associated with mannitol
infusion and reversal with ultrafiltration and hemodialysis. Nephron. 1996;73:733–734.
157. van Hengel P, Nikken JJ, de Jong GM, et al. Mannitol
-induced acute renal failure. Neth J Med. 1997;50:21–24.
158. Visweswaran P, Massin EK, Dubose TD Jr. Mannitol
-induced acute renal failure. J Am Soc Nephrol. 1997;8:1028–1033.
159. Haviv DYS. Hyponatraemia-Hyperosmolarity Associated with Intravenous Mannitol
[J]. Clinical Drug Investigation. 2000;20:287–289.
160. Matsumura M. Mannitol
-induced toxicity in a diabetic patient receiving losartan. Am J Med. 2001;110:331.
161. Perez-Perez AJ, Pazos B, Sobrado J, et al. Acute renal failure following massive mannitol
infusion. Am J Nephrol. 2002;22:573–575.
162. Tsai SF, Shu KH. Mannitol
-induced acute renal failure. Clin Nephrol. 2010;74:70–73.
163. Hacihamdioğlu DÖ, Hacihamdioğlu B, Aydemir G. Mannitol
induced acute kidney injury during treatment of cerebral edema due to diabetic ketoacidosis in an adolescent. Nobel Medicus. 2015;11:93–96.
164. Debout J, Lesoin F, Krivosic-Horber R, et al. Delayed frontal hematoma induced by mannitol
. Presse Med. 1983;12:1775–1776.
165. Rosenorn J, Westergaard L, Hansen PH. Mannitol
-induced rebleeding from intracranial aneurysm. Case report. J Neurosurg. 1983;59:529–530.
166. Nakao M, Kawaguchi R, Nakatani K, et al. Acute brain expansion during emergency neck clipping surgery for cerebral aneurysms in a patient with dilated cardiomyopathy. Masui. 1996;45:725–730.
167. Sankar T, Assina R, Karis JP, et al. Neurosurgical implications of mannitol
accumulation within a meningioma and its peritumoral region demonstrated by magnetic resonance spectroscopy: case report. J Neurosurg. 2008;108:1010–1013.
168. Hatano H, Fukami M, Yano K, et al. Side effect after intravenously administered mannitol
. Folia Ophthalmol Jpn. 1978;29:1497–1502.
169. Robinson GS, Wiese WH. Pulmonary embolism during mannitol
therapy. Chest. 1980;77:432–433.
170. Biro P, Schmid P, Wuthrich B. A life-threatening anaphylactic reaction following mannitol
. Anaesthesist. 1992;41:130–133.
171. Yamashita K, Yokoyama T, Nishiyama T, et al. A case of sudden occurrence of complete left bundle branch block during emergency surgery. Masui. 2006;55:206–208.
172. Bigard MA, Gaucher P, Lassalle C. Fatal colonic explosion during colonoscopic polypectomy. Gastroenterology. 1979;77:1307–1310.
173. Raillat A, de Saint-Julien J, Abgrall J. Colonic explosion during an endoscopic electrocoagulation after preparation with mannitol
. Gastroenterol Clin Biol. 1982;6:301–302.
174. Zanoni CE, Bergamini C, Bertoncini M, et al. Whole-gut lavage for surgery. A case of intraoperative colonic explosion after administration of mannitol
. Dis Colon Rectum. 1982;25:580–581.
175. Bonnet YY, Haberer JP, Schutz R, et al. Explosion of intestinal gas during surgery. Ann Fr Anesth Reanim. 1983;2:431–435.
176. Bouhours G, Tesson B, De Bourmont S, et al. Intestinal gas explosion during operation: a case report. Ann Fr Anesth Reanim. 2003;22:366–368.
177. Weber HP Jr. Mannitol
intoxication. Physiologic consequences of overdose. J Kans Med Soc. 1983;84:459–460; 495.
178. Domaingue CM, Nye DH. Hypotensive effect of mannitol
administered rapidly. Anaesth Intensive Care. 1985;13:134–136.
179. Losasso TJ, Muzzi DA, Cucchiara RF. Doppler detection of intravenous mannitol
crystals mimics venous air embolism. Anesth Analg. 1990;71:568–569.
180. Chang KA, Jawan B, Luk HN, et al. Bullous eruptions caused by extravasation of mannitol
--a case report. Acta Anaesthesiol Sin. 2001;39:195–198.
181. Edwards JJ, Samuels D, Fu ES. Forearm compartment syndrome from intravenous mannitol
extravasation during general anesthesia. Anesth Analg. 2003;96:245–246.
182. Erickson BA, Yap RL, Pazona JF, et al. Mannitol
extravasation during partial nephrectomy leading to forearm compartment syndrome. Int Braz J Urol. 2007;33:68–71; discussion 71.
183. Vacca VM Jr. Vesicant extravasation. Nursing. 2013;43:21–22.
184. Lightner DD, De Braganca K, Gilheeney SW, et al. A case of mannitol
hypersensitivity. J Pediatr Hematol Oncol. 2013;35:e274–e275.
185. Aviram A, Pfau A, Czaczkes JW, et al. Hyperosmolality with hyponatremia, caused by inappropriate administration of mannitol
. Am J Med. 1967;42:648–650.
186. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–1589.
187. Filippatos TD, Liamis G, Christopoulou F, et al. Ten common pitfalls in the evaluation of patients with hyponatremia. Eur J Intern Med. 2016;29:22–25.
188. Liamis G, Liberopoulos E, Barkas F, et al. Spurious electrolyte disorders: a diagnostic challenge for clinicians. Am J Nephrol. 2013;38:50–57.
189. Manninen PH, Lam AM, Gelb AW, et al. The effect of high-dose mannitol
on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth. 1987;34:442–446.
190. Lilien OM, Jones SG, Mueller CB. The mechanism of mannitol
diuresis. Surg Gynecol Obstet. 1963;117:221–228.
191. Roberts BE, Smith PH. Hazards of mannitol
infusions. Lancet. 1966;288:421–422.